Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of BMF-219 in Healthy Adult Subjects and in Adult Subjects With Type 2 Diabetes Mellitus (T2D)

ClinicalTrials.gov ID: NCT05731544

Public ClinicalTrials.gov record NCT05731544. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, PK, and PD of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adults and Adults With T2D

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 1/ 2 Randomized, Double-Blind, Placebo-Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMF-219, an Oral Covalent Menin Inhibitor, in Healthy Adult Subjects and in Adult Subjects with Type 2 Diabetes Mellitus.

Study identification

NCT ID
NCT05731544
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Biomea Fusion Inc.
Industry
Enrollment
443 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 17, 2022 (Actual)
Primary completion
Nov 18, 2024 (Actual)
Completion
Jul 8, 2025 (Actual)
Last update posted
Nov 10, 2025

2022 – 2025

United States locations

U.S. sites
36
U.S. states
13
U.S. cities
31
Facility City State ZIP Site status
Hope Clinical Research Canoga Park California 91303 —
Ark Clinical Research, LLC Fountain Valley California 92708 —
Velocity Clinical Research La Mesa California 91942 —
Ark Clinical Research Long Beach California 90815 —
Catalina Research Institute, LLC Montclair California 91763 —
Metro Clinical Trials San Bernardino California 92404 —
Southwest General Healthcare Center Fort Myers Florida 33907 —
G+C Research Group Hialeah Florida 33010 —
Sunbright Health Research Centers Homestead Florida 33032 —
Avantis Clinical Research Miami Florida 33155 —
Century Research LLC Miami Florida 33173 —
Entrust Clinical Research Miami Florida 33176 —
Panax Clinical Research Miami Lakes Florida 33014 —
David Kavtaradze MD, Inc Cordele Georgia 31015 —
Privia Medical Group Savannah Georgia 31406 —
Cedar Crosse Research Center Chicago Illinois 60607 —
IMA Clinical Research St. Louis St Louis Missouri 63117 —
Santa Rosa Medical Centers of Nevada Las Vegas Nevada 89119 —
Omera Health Brooklyn New York 11220 —
IMA Clinical Research Manhattan New York New York 10036 —
Carolina Research Center Shelby North Carolina 28150 —
Wake Forest Health Network, LLC, Medical Plaza Winston-Salem North Carolina 27104 —
Diabetes and Endocrinology Associates of Stark County Canton Ohio 44718 —
Medical Care, LLC Elizabethton Tennessee 37643 —
IMA Clinical Research Austin Texas 78745 —
Velocity Clinical Research Dallas Texas 75230 —
Zenos Clinical Research Dallas Texas 75230 —
Synergy Groups Medical LLC Houston Texas 77036 —
Synergy Group Medical Houston Texas 77061 —
Synergy Group Medical Missouri City Texas 77459 —
Clinical Trials of Texas, LLC San Antonio Texas 78229 —
Diabetes & Glandular Disease Clinic, P.A. San Antonio Texas 78229 —
Simcare Medical Research Sugar Land Texas 77478 —
Velocity Clinical Research Waco Texas 76710 —
Velocity Clinical Research Jordan Utah 84088 —
Manassas Clinical Research Manassas Virginia 20110 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05731544, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 10, 2025 · Synced Oct 23, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05731544 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →